America’s Essential Hospitals in a May 18 letter urged the Health Resources and Services Administration (HRSA) to implement a final rule establishing the calculation of ceiling prices under the 340B Drug Pricing Program and imposing civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities.
The recommendation came in response to a proposal to further delay implementation of the rule — from July 1, 2018, to July 1, 2019. The final rule was issued in 2017, but its implementation has been delayed several times.
In its comments, America’s Essential Hospitals emphasized that the final rule is an important step to ensuring transparency and accountability within the 340B program. The association also encouraged HRSA to follow directions from Congress, issued in 2010, that instructed the agency to implement such regulations.
Contact Senior Director of Policy Erin O’Malley at email@example.com or 202.585.0127 with questions.